Multiple Myeloma

Experts in multiple myeloma comment on standard induction therapy for patients with newly diagnosed symptomatic myeloma and consider recommended triplet regimens.

The BNT162b2 mRNA COVID-19 vaccine may demonstrate decreased efficacy in patients with certain types of hematologic cancers, such as chronic lymphocytic leukemia and multiple myeloma.

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss the diagnostic work-up for a patient with newly diagnosed multiple myeloma and the impact of age and frailty scores on transplant eligibility.

The FDA has approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro) plus pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy, including lenalidomide and a proteasome inhibitor

Although the armamentarium of multiple myeloma is rich with available treatment options, novel triplet regimens, maintenance therapies, and targets beyond BCMA are further expanding the paradigm across the newly diagnosed, early-relapse, and late-relapse disease states.

The combination of INN melphalan flufenamide and dexamethasone was found to induce a superior progression-free survival benefit over pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma who had previously received 2 to 4 lines of therapy, meeting the primary end point of the phase 3 OCEAN trial.

Adam Sperling, MD, PhD, discusses future research directions with idecabtagene vicleucel for the treatment of patients with multiple myeloma.

Faith Davies, MD, discusses the approval of isatuximab-irfc-based combinations for patients with relapsed/refractory multiple myeloma.

Faith E. Davies, MD, discusses the next steps for CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

Omar Nadeem, MD, discusses the integration of isatuximab-irfc in relapsed/refractory multiple myeloma.

Thomas G. Martin, MD, speaks to the FDA approval of isatuximab, carfilzomib, and dexamethasone, and potential future directors for isatuximab.

Key opinion leaders remark about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.

Factors to consider when choosing the optimal treatment approach after the first relapse of multiple myeloma.

The European Commission has granted marketing authorization for the expanded use of subcutaneous daratumumab for use in 2 new indications.

Giada Bianchi, MD, discusses diagnostic factors for light chain amyloidosis.

Omar Nadeem, MD, discusses the emergence of quadruplet regimens in multiple myeloma.

The expanding therapeutic landscape in multiple myeloma is poised to integrate daratumumab-based quadruplet therapies and novel cellular therapies as standard options for patients with newly diagnosed and relapsed/refractory disease.

C. Ola Landgren, MD, PhD, focuses on the cellular- and immunotherapy-based elements from the event and where these modern therapies optimally fit in multiple myeloma.

James Hoffman, MD, and Joshua Richter, MD, discuss the IKEMA study, the appropriate selection of therapy, and the differences between various options.

Experts in the field of multiple myeloma discuss the BOSTON trial, the study design, and the benefits of using selinexor in a patient after CAR T-cell therapy.

Daratumumab-based quadruplet regimens and cutting-edge immune-based therapies are positioned to become potential standard options in frontline multiple myeloma treatment.

Adam Sperling, MD, PhD, discusses the rationale to evaluate cellular therapy in multiple myeloma.

Faith E. Davies, MD, discusses the how to approach patients with high-risk myeloma, as well as how isatuximab and CAR T-cell therapies fit best for that patient population.

C. Ola Landgren, MD, PhD, discusses key safety considerations with a novel carfilzomib quadruplet regimen in patients with newly diagnosed multiple myeloma, the clinical implications of the phase 2 MANHATTAN trial, and next steps for this research.

Quadruplet regimens, such as those with daratumumab, are on the rise in the frontline treatment of patients with multiple myeloma, and the FDA approval of the first BCMA-targeted CAR T-cell therapy idecabtagene vicleucel represents the monumental advance made in the relapsed/refractory setting.

C. Ola Landgren, MD, PhD, discusses important research efforts that led to the launch of the phase 2 MANHATTAN trial, the results achieved with the weekly carfilzomib quadruplet regimen in patients with newly diagnosed multiple myeloma, and the potential for this approach irrespective of transplant eligibility status.

Faith Davies, MD, discusses future research directions with isatuximab in the treatment of patients with multiple myeloma.

For patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant status, daratumumab plus cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses.

Ciltacabtagene autoleucel continued to yield early, deep, and durable responses after longer follow-up in patients with relapsed/refractory multiple myeloma.

Neurologic adverse effect associated with CAR T-cell therapies like ciltacabtagene autoleucel can be managed without long-term lasting effects, as long as they are caught and treated promptly in patients with relapsed/refractory multiple myeloma.